within Pharmacolibrary.Drugs.ATC.C;

model C09CA05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.3,
    Cl             = 0.00016666666666666666,
    adminDuration  = 600,
    adminMass      = 200 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.05,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.013333333333333334,
    Tlag           = 10.200000000000001
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C09CA05</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Tasosartan is a non-peptide angiotensin II receptor antagonist (ARB) that was developed for the treatment of hypertension. It acts by blocking the binding of angiotensin II to the AT1 receptor, resulting in vasodilation and reduced blood pressure. Tasosartan underwent clinical trials, but development was discontinued and it is not an approved or marketed drug.</p><h4>Pharmacokinetics</h4><p>Estimated typical pharmacokinetic parameters for orally administered tasosartan in healthy adult subjects, as published reference PK data are not available.</p><h4>References</h4><ol><li><p>Brunner, HR (1997). The new angiotensin II receptor antagonist, irbesartan: pharmacokinetic and pharmacodynamic considerations. <i>American journal of hypertension</i> 10(12 Pt 2) 311S–317S. DOI:<a href=&quot;https://doi.org/10.1016/s0895-7061(97)00391-9&quot;>10.1016/s0895-7061(97)00391-9</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/9438775/&quot;>https://pubmed.ncbi.nlm.nih.gov/9438775</a></p></li><li><p>Maillard, MP, et al., &amp; Burnier, M (2000). Tasosartan, enoltasosartan, and angiotensin II receptor blockade: the confounding role of protein binding. <i>The Journal of pharmacology and experimental therapeutics</i> 295(2) 649–654. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11046101/&quot;>https://pubmed.ncbi.nlm.nih.gov/11046101</a></p></li><li><p>Ellingboe, JW, et al., &amp; Park, CH (1994). Pyrido[2,3-d]pyrimidine angiotensin II antagonists. <i>Journal of medicinal chemistry</i> 37(4) 542–550. DOI:<a href=&quot;https://doi.org/10.1021/jm00030a013&quot;>10.1021/jm00030a013</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8120871/&quot;>https://pubmed.ncbi.nlm.nih.gov/8120871</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C09CA05;
